Featured Story

  • Novo will soon open plant in Russia

    The Russian ruble maybe in rubble, but the economic challenges will not deter Novo Nordisk, which is finishing up a plant in Russia. Five years in the planning and nearly three in construction, execs say it is needed to fulfill the drugmaker's long-term goals there.

Hospira recalls more saline after human hair found in a bag

A loose hair has contributed to the nationwide shortage of saline solution, as Hospira recalls another lot of the commonly used product.

Another Turkish man sentenced for smuggling fake cancer drugs into U.S.

With the sentencing of a second man from Turkey, federal authorities have essentially brought to a close a case stemming from the appearance in the U.S. of counterfeit and unapproved cancer drugs. The drugs were sold to wholesalers and physician practices throughout the U.S., in some cases making patients ill.

China grants GMP-approved facility for Tianyin Pharmaceutical

SINGAPORE--The Qionglai Tianyin Facility of Tianyin Pharmaceutical received its Good Manufacturing Practice certificate from the China Food and Drug Administration this week, notching up an important certificate to be able to sell at home and abroad.

China's 3SBio buys Sirton for play in injectables

China-based biotechnology company 3SBio bought the entire share capital of Italy-based pharmaceutical contract manufacturing company Sirton Pharmaceuticals from First Shanghai, the company said on Jan. 26.

BASF invests $63M in PVP manufacturing operations

BASF intends to invest more than $63 million to build a polyvinylpyrrolidone (PVP) plant in Shanghai, China, as well as expanding capacity at plants in plants in Ludwigshafen, Germany, and Geismar, LA. 


From Our Sister Sites


Valeant Pharmaceuticals wasn't kidding when it said it was ready to rumble with new promotional spending. Its anti-fungal treatment for toenails, Jublia, will go to the Super Bowl this Sunday....


Pfizer got a federal judge to toss an investor lawsuit last year tied its now-withdrawn pain drug Bextra. But it wasn't the only investor suit raising similar issues, namely that the board had not been forthright about issues with the drugs. Another was just days away from trial, that is until the drugmaker agreed to settle it for $400 million.